Acuta Capital Partners, LLC Trevi Therapeutics, Inc. Transaction History
Acuta Capital Partners, LLC
- $70.3 Million
- Q4 2024
A detailed history of Acuta Capital Partners, LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 771,958 shares of TRVI stock, worth $5.11 Million. This represents 4.67% of its overall portfolio holdings.
Number of Shares
771,958
Previous 290,500
165.73%
Holding current value
$5.11 Million
Previous $970,000
238.97%
% of portfolio
4.67%
Previous 0.98%
Shares
5 transactions
Others Institutions Holding TRVI
# of Institutions
114Shares Held
77.6MCall Options Held
218KPut Options Held
182K-
Nea Management Company, LLC Timonium, MD11.4MShares$75.3 Million3.46% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.7MShares$70.6 Million2.72% of portfolio
-
Viking Global Investors LP4.4MShares$29.1 Million0.06% of portfolio
-
Rubric Capital Management LP New York, NY4.21MShares$27.8 Million0.3% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.15MShares$27.5 Million0.04% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $386M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...